High-cited favorable studies for COVID-19 treatments ineffective in large trials

John P.A. Ioannidis

Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA

Address correspondence to: John P.A. Ioannidis, Stanford Prevention Research Center, Medical School Office Building, Room X306, 1265 Welch Road, Stanford CA 94305, USA. E-mail: jioannid@stanford.edu

Word count: 2726; abstract: 258; 2 tables; 1 figure; 1 supplementary table

ABSTRACT

Importance. COVID-19 has resulted in massive production, publication and wide dissemination of clinical studies trying to identify effective treatments. However, several widely touted treatments failed to show effectiveness in large well-done randomized controlled trials (RCTs).
Objective. To evaluate for COVID-19 treatments that showed no benefits in subsequent large RCTs how many of their most-cited clinical studies had declared favorable results for these interventions.

Methods. Scopus (last update December 23, 2021) identified articles on lopinavir-ritonavir, hydroxycholoroquine/azithromycin, remdesivir, convalescent plasma, colchicine or interferon (index interventions) that represented clinical trials and that had received >150 citations. Their conclusions were assessed and correlated with study design features. The ten most recent citations for the most-cited article on each index intervention were examined on whether they were critical to the highly-cited study. Altmetric scores were also obtained.

Findings. 40 articles of clinical studies on these index interventions had received >150 citations (7 exceeded 1,000 citations). 20/40 (50%) had favorable conclusions and 4 were equivocal. Highly-cited articles with favorable conclusions were rarely RCTs while those without favorable conclusions were mostly RCTs (3/20 vs 15/20, p=0.0003). Only 1 RCT with favorable conclusions had sample size >160. Citation counts correlated strongly with Altmetric scores, in particular news items. Only 9 (15%) of 60 recent citations to the most highly-cited studies with favorable or equivocal conclusions were critical to the highly-cited study.

Conclusion. Many clinical studies with favorable conclusions for largely ineffective COVID-19 treatments are uncritically heavily cited and disseminated. Early observational studies and small randomized trials may cause spurious claims of effectiveness that get perpetuated.

Keywords: randomized controlled trials, non-randomized studies, COVID-19, bias

INTRODUCTION

The search for COVID-19 treatments has ushered in thousands of clinical studies,¹⁻³ many promises, several emergency authorizations, and some excellent successes. In particular, large adaptive randomized controlled trials (RCTs) using rapid recruitment of participants from real-world clinical practice were instrumental in documenting benefits with large-scale evidence.^{4,5} By the end of 2021 dexamethasone, tocilizumab, and monoclonal antibody combinations had shown convincing evidence that they reduce mortality in various patient groups and clinical settings.⁶⁻⁸ However, the largest randomized controlled trials (RCTs) to-date, RECOVERY⁹⁻¹³ and SOLIDARITY,¹⁴ have also showed no benefit for several other treatments. These treatments include lopinavir/ritonavir,⁹ hydroxycholoroquine,^{10,14} azithromycin,¹¹ remdesivir,¹⁴ convalescent plasma,¹² colchicine¹³ and interferon.¹⁴ All these interventions with disappointing results in the large trials had been touted as being highly promising and effective in earlier, mostly smaller studies. Each of these treatments have been debated heavily in both scientific and lay circles, often vehemently so. The unfavorable results of the large trials have also led in several situations to reversals of emergency authorizations and/or removal of these interventions from the list of recommended treatments in guidelines.

The ability of the scientific literature to move forward and adopt the newer, more sober evidence is unknown. Important questions can be asked. Has the emergence of the unfavorable results from the large, carefully conducted RCTs managed to change the pervasive presence of these treatments in the scientific literature? Do authors continue to cite the highly promising early clinical studies with the favorable results? If so, are these citations critical of the original promising studies and do they cite also the well-powered and carefully executed RCTs that had null results? The present analysis aimed to evaluate how many of the most-cited clinical studies in the literature have been favorable for interventions that failed to show a survival benefit for COVID-19 patients in the two largest, well-powered RCTs, RECOVERY⁹⁻¹³ and SOLIDARITY.¹⁴ The analysis also aimed to evaluate whether study design features are associated with favorable conclusions; how citations have tracked against media and social media interest (as captured by the Altmetric score); and whether citing articles to the most-cited studies were critical and whether they cited also the refuting large RCTs.

METHODS

Eligible highly cited studies and search strategy

A Scopus search (last update 12/23/2021) sought articles published in 2020-2021 with lopinavir-ritonavir, hydroxycholoroquine, azithromycin, remdesivir, convalescent plasma, colchicine or interferon (title-abstract-keywords). Articles were eligible if they were clinical studies that pertained to any of these index interventions and that had received over 150 citations in Scopus by the search date. The citation threshold was pre-specified but it is arbitrary. For articles published very recently, >150 citations is extremely rare (<1% of total). Therefore, these articles are exceptionally influential in the scientific literature.

The index treatments were selected because they have been evaluated in the two largest RCTs of therapeutic interventions for COVID-19 and have shown no significant benefit for the primary outcome of mortality and no other signals of any substantive benefit for other clinically important outcomes. The relative risks for the mortality outcome in RECOVERY was 1.03 (95% confidence interval [CI] 0.91-1.17) based on 5040 randomized participants for lopinavir-ritonavir,⁹ 1.09 (95% CI, 0.97-1.23) based on 4716 randomized participants for hydroxychloroquine,¹⁰ 0.97 (95% CI, 0.87-1.07) based on 7763 randomized participants for

azithromycin,¹¹ 1.00 (95% CI, 0.93-1.07) based on 11558 randomized participants for convalescent plasma,¹² and 1.01 (95% CI 0.93-1.10) based on 11340 randomized participants for colchicine.¹³ The relative risks for the mortality outcome in SOLIDARITY,¹⁴ a trial sponsored by the World Health Organization to assess repurposed drugs for COVID-19,¹³ were 0.95 (95% CI, 0.81-1.11) based on 5451 randomized participants for remdesivir, 1.19, 95% CI, 0.89-1.59) based 1853 randomized participants for remdesivr, 1.00 (95% CI, 0.79-.125) based on 2771 randomized participants for lopinavir, and 1.16 (95% CI, 0.96-1.39) based on 4100 randomized participants for interferon.

Among the highly-cited articles retrieved on these index treatments, any study design was eligible (RCT, non-randomized controlled, uncontrolled study [including also case reports and case series]). Clinical studies where the index intervention(s) was involved along with other treatment(s) were also eligible, unless the clinical study focused on the other treatment(s) (e.g. tested a new treatment versus standard of care and used an index intervention as a common backbone for both arms) or found that a new treatment is superior to an index intervention (in which case, one cannot conclude whether the index intervention by itself is effective or not). Retracted articles and their retraction notices were also excluded.

Data extraction

Data extraction on the eligible highly-cited studies recorded the evaluated interventions, the design (randomized or not), sample size, and number of deaths. The conclusions of the authors of each eligible highly-cited study were categorized as favorable (claiming a benefit and/or safety without harm for an index treatment); unfavorable (claiming no benefit and/or a safety problem for an index treatment); or equivocal when there was a mixed message or potential benefit seen in some particular analysis or endpoint.

Media and social media impact

Media and social media impact was assessed by the Altmetric score. Information was also obtained through Altmetric on the rank of the paper across all scientific papers tracked by Altmetric and on the number of news items and tweets mentioning each highly-cited paper. Correlations between citation counts and Altmetric score, news items, and tweets were estimated with Pearson coefficients.

Citation content analysis

For each index treatment, the 10 most recent citing papers to its most highly-cited study with favorable or equivocal results were probed to assess whether the citations were critical to the highly-cited study and to identify whether the citing papers also cited the large trials with unfavorable results (RECOVERY and/or SOLIDARITY)⁹⁻¹⁴ – either the final peer-reviewed publications, or the preprints, or at least some press release or other mention of these unfavorable results. Unfavorable results were announced by RECOVERY for hydroxychloroquine on June 5, 2020, for lopinavir-ritonavir on June 29, 2020, for azithromycin of December 14, 2020, for convalescent plasma on January 15, 2020, and for colchicine on March 5, 2021 and by SOLIDARITY on hydroxychloroquine, remdesivir, lopinavir, and interferon on October 15, 2020. Therefore, it is very likely that there was sufficient time for the authors of the examined citing papers to be aware of these results when they wrote or at least when they revised their papers. The most recent citing papers as of December 27, 2021 were retrieved from Scopus.

RESULTS

Highly-cited clinical studies on COVID-19 index treatments

The Scopus search yielded 63803 results, of which 465 published items were highly-cited with >150 citations. 45 of the 465 pertained to any of the index interventions being used in

clinical studies. A retracted paper and its retraction notice were excluded, and another 3 were excluded because the favored treatment (baricitinib, arbidol) was not an index intervention. The 40 eligible articles are shown in Table 1.^{9,10,14-51}

Favorable conclusions

Of 40 eligible studies, 20 (50%) had favorable conclusions for the index treatments, 4 were equivocal and 16 were unfavorable. The unfavorable group included the publication of SOLIDARITY trial itself¹⁴ and the publications of the hydroxychloroquine¹⁰ and lopinavirritonavir⁹ assessments from the RECOVERY trial. Of 7 articles that exceeded 1,000 citations, 5 had favorable conclusions, and 2 were equivocal (one described significant benefit in modified intention-to-treat analysis, and the other mentioned a non-significant trend for clinical improvement).

Correlates of favorable conclusions

The highly-cited articles with favorable conclusions were far less likely to be randomized controlled trials than the other highly-cited articles (3/20 versus 15/20, exact p=0.0003). The few randomized controlled trials with favorable conclusions tended to be smaller than the others (median sample size 160 versus 464). Of the 6 studies with at least 200 deaths, all three randomized trials did not reach favorable conclusions; 2 of 3 non-randomized studies did.

Altmetric scores

As shown in Supplementary Table 1, all 40 highly-cited papers had very high Altmetric scores placing them at the top 5% of published papers and 24/40 had extraordinarily high Altmetric scores placing them among the 2000 highest Altmetric scored papers of all science of all times. Five papers were among the top-200 of all science of all times. There was a strong correlation between the Altmetric score and the number of citations (r=0.74) (Figure 1). The

correlation of the number of citations was stronger with the number of news items (r=0.81) and more modest with the number of tweets (n=0.47).

Favorable papers did not have higher media and social media mentions than other papers. For example, Altmetric values in the top-2000 of all science occurred in 9/20 favorable, 4/4 equivocal and 11/16 unfavorable papers (exact p=0.10 for the comparison of papers with favorable conclusions versus other papers).

Analysis of most recent citing articles

Only 9 (15%) of 60 recent citations to the most highly-cited studies with favorable or equivocal conclusions were critical to the highly-cited study (Table 2). Citing papers uncommonly (8/60, 13%) cited the respective RECOVERY or SOLIDARITY results.

DISCUSSION

This analysis demonstrates that many highly-cited clinical studies favor COVID-19 treatments that have shown no benefits in large, well-powered randomized trials. Most favorable studies are not randomized or are even uncontrolled, but they can still exercise strong, persistent influence on the scientific literature. Citation counts track well with strong presence of these studies in media and social media. The most highly-cited studies on these interventions have either entirely or partially favorable conclusions and the citations that they continue to receive are rarely critical of them.

Citations are a measure of the influence of a research paper across the broad scientific literature. Various manifestations of citation bias have been demonstrated in other clinical and scientific fields well before the COVID-19 era.⁵²⁻⁵⁷ In principle, studies with "positive" results tend to be more heavily cited than studies with "negative" results on the same topic. The citation bias creates a distorted picture for the perception of the scientific literature at large. Repeated

mention of the most favorable results gives the allusion that they are more likely to represent the truth, while this may not be the case. The COVID-19 scientific literature is also unique in terms of the massive volume of papers produced^{58,59} (and thus also citations generated) within a very limited timeframe. Very few studies in the history of medicine have ever received the number of citations received by the most highly-cited COVID-19-related papers – including those whose promises could not be validated by large, well-powered RCTs.

The highly polarized and charged situation surrounding the COVID-19 pandemic may have further complicated matters and intensified the bias. Several of these treatments have received tremendous attention not only in the scientific literature, but also in the wider society and they have both strong supporters and strong critics. Many of the highly-cited papers analyzed here have also reached astronomical Altmetric scores, due to their massive discussion in media and social media. Altmetric scores correlated well with citation counts. The correlation was more prominent when news items were considered, while tweets had a more modest correlation with citation count. Altmetric score analyses have shown⁶⁰ that media and social media attention may remain high even for fully retracted papers.

Some caveats need to be acknowledged. The most important limitation of this analysis is that the large trials may not necessarily be a perfect gold standard. No single clinical study can claim to possess the perfect truth, no matter how well it is conducted and how well it is protected from bias. The CIs of the large trials cannot exclude very small benefits on survival – or small harms. These trials have also shown no benefit also on other outcomes. However, small benefits (or harms) for these outcomes are also not possible to exclude with perfect certainty. Moreover, beneficial effects for some treatments may still exist in circumscribed, special circumstances, with different dosing regimens, and in specific patient subgroups that may have been outside the

eligibility criteria of the large RCTs or may have been under-represented in these large RCTs. However, similar concerns and speculative counter-arguments may be raised almost in any clinical topic, especially by those who still believe that a treatment may have merits despite its poor performance in very large trials.⁶¹

It should also be acknowledged that not all guidelines have removed these treatments from the list of interventions that they recommend. Remdesivir is probably the most notable example in this regard. It is not recommended by the European Respiratory Society⁶² and the World Health Organization has issued a conditional recommendation *against* its use.⁶³ Conversely, the US National Institutes of Health (NIH) list remdesivir very prominently among the very few treatments that they recommend.⁶⁴ Subjective interpretation of the evidence is obvious in these differing opinions. Moreover, there may be overlap or connection between the researchers and institutions who perform the clinical studies and those that issue the recommendations and guidelines. For example, the most-cited favorable trial on remdesivir was spearheaded by NIH.¹⁷ Moreover, a consequence of trusting a treatment as being effective is that it becomes attractive, if not necessary, to use it as background treatment or as a comparator when a new intervention is to be evaluated. In the case of remdesivir, NIH-spearheaded trials have already done this. E.g. they have compared interferon+remdesivir versus remdesivir alone and claimed to find no benefit for interferon;⁶⁵ and baricitinib+remdesivir versus remdesivir alone and claimed to find a benefit for the addition of baricitinib.⁶⁶ Retrospectively, these study designs are poor choices if remdesivir is indeed ineffective. They would be even highly misleading if remdesivir happens to be harmful.

Acknowledging these caveats and some residual uncertainty, it is more likely that these treatments overall don't save lives eventually. The most recent meta-analyses are also consistent

with this interpretation.⁶⁷⁻⁷¹ For hydroxychloroquine, a recent collaborative meta-analysis even shows nominally statistically significantly increased mortality.⁷²

Prior experience from the in-depth analysis of persistent high citations of non-validated papers in other fields may offer us insights on why this situation arose also for COVID-19 treatments. One empirical evaluation⁶¹ assessed in-depth the citation patterns of extremely highly-cited papers on the benefits of beta carotene for cancer prevention, on estrogens for Alzheimer's dementia and on alpha tocopherol for cardiovascular disease. Despite the emergence of large RCTs with unfavorable results for these interventions, the observational studies that made the original promises continued to be heavily cited long after the "negative" RCT results had been published. Their citations were either ignoring the refuting RCTs (for beta carotene), or raising numerous counterarguments against them (for estrogen and alpha tocopherol). Similarly, in psychology, where several major claims had been found to be irreproducible in preregistered reproducibility assessments done by many teams, frequent citation of the original claims has continued unperturbed after their non-reproduction.⁷³ The citing articles uncommonly take a critical stance against the original claims.⁷³ In other areas where evidence is heavily centered on biological considerations, citation networks citing some preferred papers may create a perpetuated distortion of what is the established knowledge. This has been seen in empirical evaluations in genetics of amygdala activation⁷⁴ and in pathology of inclusion body myositis.⁷⁵ Another empirical evaluation even found evidence of so-called "affirmative citation bias".⁵² The citations to the critical articles that had thoroughly debunked prior beliefs were mostly affirmative, in favor of the original beliefs that had been debunked. The authors concluded that even criticism itself may paradoxically reinforce the establishment of debunked prior beliefs.⁵²

These observations suggest that often science is organized in cliques or schools of thought that are recalcitrant to the provision and acceptance of contrarian evidence. This may have happened also in the case of the early promising COVID-19 treatments. Moreover, in COVID-19, given the vast attention devoted to the topic, the citation rates of these non-validated treatment benefits are even more extraordinary. Furthermore, the overall impact of their dissemination reverberates across wider societal circles, not just scientific groups. The advent of very large RCTs did not suffice to perturb much this intense dissemination.

In conclusion, one should avoid putting much trust to highly promising results from early observational studies and small randomized trials of new or repurposed treatments. For serious diseases, like COVID-19, evidence on mortality endpoints should be sought. Pilot studies should not be abandoned or dejected, and they do have some value in offering early insights. However, they should be seen with great caution and with tempered enthusiasm. Large trials with flexible designs that allow obtaining large-scale rigorous evidence in a timely manner have been a major success during the pandemic³⁻⁵ and their use should be promoted further.

Table 1. Clinical studies with more than 150 Scopus citations that assess COVID-19 treatments

that have shown no benefit in large trials (RECOVERY and SOLIDARITY).

Author (ref)	Interventions	Ν	RCT	>200	Favorable for	Citations
				deaths	index treatment	
Cao (15)	LPV/r vs. SOC	199	Yes	No	Equivocal (benefit in	2859
					MITT analysis)	
Gautret (16)	HCQ +/- AZ	38	No	No	Yes	2839
Beigel (17)	Remdesivir vs. placebo	1062	Yes	No	Yes	2562
Wang (18)	Remdesivir vs. placebo	237	Yes	No	Equivocal (non-	1612
					significant trend)	
Grein (19)	Remdesivir	53	No	No	Yes	1444
Shen (20)	Convalescent plasma	5	No	No	Yes	1331
Duan (21)	Convalescent plasma	10	No	No	Yes	1034
Geleris (22)	HCQ	1446	No	No	No	931
Hung (23)	LPV/r+ribavirin+interferon vs.	127	Yes	No	Yes	772
	LPV/r					
Boulware (24)	HCQ prophylaxis vs. placebo	821	Yes	No	No	688
Pan (14)*	Four active interventions (HCQ,	11330	Yes	Yes	No	646
	remdesivir, lopinavir, interferon)					
	vs. control					
Rosenberg (25)	HCQ, AZ, both, neither	1438	No	Yes	No	625
Li (26)	Convalescent plasma vs. SOC	103	Yes	No	Equivocal (benefit in	615
					severe disease and for	
					PCR conversion)	
Goldman (27)	Remdesivir 5 vs. 10 days	397	Yes	No	No	562
Tang (28)	HCQ vs. SOC	150	Yes	No	No	552

Cavalcanti (29)	HCQ vs. HCQ+AZ vs. SOC	667	Yes	No	No	510
Molina (30)	HCQ+AZ	11	No	No	No	448
Horby (10)*	HCQ vs. SOC	4716	Yes	Yes	No	430
Spinner (31)	Remdesivir vs. SOC	596	Yes	No	Equivocal (uncertain clinical value)	428
Gautret (32)	HCQ+AZ	80	No	No	Yes	396
Chen (33)	HCQ vs. control	30	Yes	No	No	322
Simonovich (34)	Convalescent plasma vs. placebo	228	Yes	No	No	311
Libster (35)	Convalescent plasma vs. placebo	160	Yes	No	Yes	276
Arshad (36)	HCQ, HCQ+AZ, AZ, neither	2541	No	Yes	Yes	267
Agarwal (37)	Convalescent plasma vs. SOC	464	Yes	No	No	262
Million (38)	HCQ+AZ	1061	No	No	Yes	246
Horby (9)*	LPV/r vs. SOC	5040	Yes	Yes	No	236
Mahevas (39)	HCQ, control	181	No	No	No	235
Skipper (40)	HCQ vs. placebo	491	Yes	No	No	232
Zhang (41)	Convalescent plasma	4	No	No	Yes	231
Ye (42)	Convalescent plasma	6	No	No	Yes	222
Magagnoli (43)	HCQ+/-AZ, control	807	No	No	No	203
Zhou (44)	Interferon or interferon+arbidol	77	No	No	Yes	198
Liu (45)	Convalescent plasma, control	39	No	No	Yes	195
Ahn (46)	Convalescent plasma	2	No	No	Yes	192
Joyner (47)	Convalescent plasma	5000	No	No	Yes	191
Joyner (48)	Convalescent plasma	20000	No	Yes	Yes	186
Zeng (49)	Convalescent plasma	6	No	No	Yes	180
Deftereos (50)	Colchicine vs. SOC	105	Yes	No	Yes	177
Saleh (51)	(HCQ or chloroquine) +/-AZ	201	No	No	Yes	162

HCQ: hydroxychloroquine; AZ: azithromycin; SOC: standard of care; LPV/r: lopinavir-

ritonavir; MITT: modified intention-to-treat

*presenting results from one of the two large randomized trials (RECOVERY and

SOLIDARITY)

Table 2. Qualitative analysis of recent citations to the most highly-cited article for each index

treatment that reached favorable or equivocal conclusions.

Intervention	Highly-	Critical citations (among 10 recent sampled citing	RECOVERY/
	cited article	articles)	SOLIDARITY
			trials cited*
LPV/r	Cao, NEJM	1/10 ("So far none of these drugs have been found to be an	0/10
		appropriate drug for COVID-19")	
HCQ+/-AZ	Gautret, Intern	3/10 ("So far none of these drugs have been found to be an	2/10
	J Antimicrob	appropriate drug for COVID-19" and "The excitement	(SOLIDARITY)
	Agents	surrounding hydroxychloroquine was fueled early on by	
		excessive media attention after a nonrandomized study (with	
		questionable, hotly debated reliability) was released" and "The	
		WHO announced the failure of the "the solidarity trial", which	
		means that hydroxychloroquine did not achieve the desired	
		effect in the treatment of COVID-19.")	
Remdesivir	Beigel, NEJM	2/10 ("So far none of these drugs have been found to be an	2/10
		appropriate drug for COVID-19 WHO have made a	(SOLIDARITY)
		conditional recommendation against the use of Remdesivir for	
		hospitalised Covid patients, regardless of the disease's severity,	
		because of lack of evidence showing that it improves survival	
		rate" and "had little or no effect on overall mortality, initiation	
		of ventilation, or duration of hospital stay")	
Convalescent	Shen, JAMA	2/10 ("Small studies using convalescent serum for SARS-CoV-2	1/10
plasma		patients suggested that treatment was well tolerated, reduced	(RECOVERY)
		viraemia and clinical symptoms (Shen et al., 2020, Duan et al.,	
		2020), whereas the larger RECOVERY Collaborative Group	
		(2021c), testing convalescent plasma as a treatment in life-	


		threatening COVID-19 did not result in significant improvement and was discontinued early" and "the clinical effect of this CP intervention has not yet been determined, since patients could have recovered due to other treatments administrated in parallel"	
Interferon	Hung, Lancet	0/10	2/10 (SOLIDARITY)
Colchicine	Deftereos, JAMA Network Open	1/10 ("in this large, well powered trial, we found no evidence of a benefit from colchicine")**	1/10 (RECOVERY)


LPV/r: lopinavir-ritonavir, HCQ: hydroxychloroquine; AZ: azithromycin

*Citation to either the respective publication of RECOVERY or SOLIDARITY on that

intervention or to some preliminary press release or other statement about the trial results.

**this statement comes from the article publication of the RECOVERY colchicine trial itself





Supplementary Table 1. Altmetric scores for the highly cited clinical studies

Author, Journal	Altmetric	Rank	News	Tweets	Favorable for
	score				index treatment
Cao, NEJM	8706	199	338	8076	Equivocal
Gautret, Int J	10011	145	317	10429	Yes
Antimicrob Agents					
Beigel, NEJM	13185	75	654	11351	Yes
Wang, Lancet	11569	101	425	13922	Equivocal
Grein, NEJM	8558	202	312	9531	Yes
Shen, JAMA	13624	68	216	34897	Yes
Duan, PNAS	4646	654	193	5845	Yes
Geleris, NEJM	8548	204	251	8299	No
Hung, Lancet	2162	2623	152	1386	Yes
Boulware, NEJM	10092	141	425	8663	No
Pan, Lancet	3790	944	108	5144	No
Rosenberg, JAMA	5931	431	185	5916	No
Li, JAMA	3784	948	122	4276	Equivocal
Goldman, NEJM	1056	9234	51	934	No
Tang, BMJ	4761	619	166	4945	No
Cavalcanti, NEJM	6592	346	109	7157	No
Molina, MMI	4761	618	93	5757	No
Horby, NEJM	3183	1289	63	3625	No
Spinner, JAMA	2931	1515	116	2989	Equivocal
Gautret, Travel Med	615	23380	9	683	Yes
Infect Dis					
Chen, Zheijang	331	64107	30	46	No

Libster, NEJM 2881 1555 151 2325 Arshad, Intern J 8447 208 136 13513 Infect Did 4993 86 1116 Million, Travel Med 5270 518 14 11079 Infect Dis 1660 4160 93 1490 Mahevas, BMJ 3523 1089 53 10109 Skipper, Ann Intern 3883 915 118 4990 Med 102 283112 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 311 70045 16 296 Ahn, J Korean Med 83 349532 6 29 5 Sci 128 216887 13 30 9 Joyner, J Clin Invest 304 71692 32 80 Joyner, J Solinic 128 216887 13 30 <t< th=""><th>No</th></t<>	No
Infect Did I494 4993 86 1116 Agarwal, BMJ 1494 4993 86 1116 Million, Travel Med 5270 518 14 11079 Infect Dis 1 1 1107 1 Horby, Lancet 1660 4160 93 1490 Mahevas, BMJ 3523 1089 53 10109 Skipper, Ann Intern 3883 915 118 4990 Med 1 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 1 1 2 2 1 1 Liu, Nat Med 311 70045 16 296 3 349532 6 29 Sci 1 30 1 30 1 30 1 30 1 30 1 30 <td< td=""><td>Yes</td></td<>	Yes
Agarwal, BMJ 1494 4993 86 1116 Million, Travel Med 5270 518 14 11079 Infect Dis 1660 4160 93 1490 Mahevas, BMJ 3523 1089 53 10109 Skipper, Ann Intern 3883 915 118 4990 Med 102 283112 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 111 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 128 216887 13 30 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	Yes
Million, Travel Med 5270 518 14 11079 Infect Dis 1660 4160 93 1490 Mahevas, BMJ 3523 1089 53 10109 Skipper, Ann Intern 3883 915 118 4990 Med 102 283112 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 11 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 11 100 10 10 Liu, Nat Med 311 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 10 128 216887 13 30 Joyner, Mayo Clinic 128 216887 13 30 P	
Infect Dis Image: Matrix and the second	No
Horby, Lancet16604160931490Mahevas, BMJ352310895310109Skipper, Ann Intern38839151184990Med2831122117Ye, J Med Virol84345859532Magagnoli, Med*411XXX30203Zhou, Front6382200775111Immunol117004516296Ahn, J Korean Med83349532629Sci1282168871330Joyner, J Clin Invest304716923280Joyner, Mayo Clinic1282168871330Proc11813650315110Deftereos, JAMA8761286633863	Yes
Mahevas, BMJ 3523 1089 53 10109 Skipper, Ann Intern 3883 915 118 4990 Med 102 283112 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 11 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 10 71692 32 80 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 2 216887 15 110 Deftereos, JAMA 876 12866 33 863	
Skipper, Ann Intern 3883 915 118 4990 Med 102 283112 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 10 10 203 203 Liu, Nat Med 311 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 1 128 216887 13 30 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	No
Med 102 283112 2 117 Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 102 283112 2 203 Liu, Nat Med 311 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 128 216887 13 30 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 2 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	No
Zhang, Chest1022831122117Ye, J Med Virol84345859532Magagnoli, Med*411XXX30203Zhou, Front6382200775111Immunol116296Ahn, J Korean Med83349532629Sci304716923280Joyner, J Clin Invest304716923280Joyner, Mayo Clinic1282168871330Proc11813650315110Deftereos, JAMA8761286633863	No
Ye, J Med Virol 84 345859 5 32 Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 10 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 10 128 216887 13 30 Joyner, J Clin Invest 304 71692 32 80 Joyner, J Clin Invest 304 71692 32 80 Joyner, J Clin Invest 128 216887 13 30 Proc 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	
Magagnoli, Med* 411 XXX 30 203 Zhou, Front 638 22007 75 111 Immunol 11 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 10 216887 13 30 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	Yes
Zhou, Front6382200775111Immunol117004516296Ahn, J Korean Med83349532629Sci1716923280Joyner, J Clin Invest304716923280Joyner, Mayo Clinic1282168871330Proc11813650315110Deftereos, JAMA8761286633863	Yes
Immunol Immunol Immunol Immunol Liu, Nat Med 311 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci Immunol 10 10 296 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc Immunol 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	No
Liu, Nat Med 311 70045 16 296 Ahn, J Korean Med 83 349532 6 29 Sci 304 71692 32 80 Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 2 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	Yes
Ahn, J Korean Med 83 349532 6 29 Sci Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	
Sci Image: Sci state of the state of	Yes
Joyner, J Clin Invest 304 71692 32 80 Joyner, Mayo Clinic 128 216887 13 30 Proc 216887 13 30 Zeng, J Infect Dis 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	Yes
Joyner, Mayo Clinic 128 216887 13 30 Proc 216887 13 30 Zeng, J Infect Dis 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	
Proc Image: Constraint of the second se	Yes
Zeng, J Infect Dis 118 136503 15 110 Deftereos, JAMA 876 12866 33 863	Yes
Deftereos, JAMA 876 12866 33 863	
	Yes
Network Open	Yes
Saleh, Circ: Arrh 2834 1609 2 10329	Yes
Electrophysiol	

*a medRxiv preprint of the same study received far greater attention (Altmetric score 8898, Altmetric rank 187, 413 news, 8715 tweets)

REFERENCES

- Janiaud P, Axfors C, Van't Hooft J, Saccilotto R, Agarwal A, Appenzeller-Herzog C, Contopoulos-Ioannidis DG, Danchev V, Dirnagl U, Ewald H, Gartlehner G, Goodman SN, Haber NA, Ioannidis AD, Ioannidis JPA, Lythgoe MP, Ma W, Macleod M, Malički M, Meerpohl JJ, Min Y, Moher D, Nagavci B, Naudet F, Pauli-Magnus C, O'Sullivan JW, Riedel N, Roth JA, Sauermann M, Schandelmaier S, Schmitt AM, Speich B, Williamson PR, Hemkens LG. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Res. 2020 Oct 2;9:1193.
- 2. Lee JJ, Price JC, Jackson WM, Whittington RA, Ioannidis JPA. COVID-19: A catalyst for transforming randomized trials. J Neurosurg Anesthesiol. 2022 Jan 1;34(1):107-112.
- Janiaud P, Hemkens LG, Ioannidis JP. Lessons learned from COVID-19 trials: should we be doing trials differently? Canadian Journal of Cardiology 2021 May 30:S0828-282X(21)00285-3.
- Pessoa-Amorim G, Campbell M, Fletcher L, Horby P, Landray M, Mafham M, Haynes R. Making trials part of good clinical care: lessons from the RECOVERY trial. Future Healthc J. 2021 Jul;8(2):e243-e250.
- Pessoa-Amorim G, Campbell M, Fletcher L, Horby P, Landray M, Mafham M, Haynes R. Making trials part of good clinical care: lessons from the RECOVERY trial. Future Healthc J. 2021 Jul;8(2):e243-e250.
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645.

- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.
- 8. RECOVERY Collaborative Group, Peter W Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, David M Weinreich, Richard Haynes, Martin J Landray. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv 2021.06.15.21258542.
- RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4.
- 10. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E,

> Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926.

- RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5.
- RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7.
- RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4.
- 14. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle

> S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184.

- 15. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. New England Journal of Medicine 2020;382(19):1787-1799.
- 16. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 2020:56(1):art. no. 105949.
- 17. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 —
 Final report. New England Journal of Medicine 2020;383(19):1813-1826.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569-1578.
- 19. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine 2020;382(24):2327-2336.
- 20. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA 2020;323(16):1582-1589.
- 21. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America 2020;117(17):9490-9496.
- 22. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. New England Journal of Medicine 2020;382(25):2411-2418.

- 23. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238):1695-1704.
- 24. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England journal of medicine 2020;383(6):517-525.
- 25. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. JAMA 2020;323(24):2493-2502.
- 26. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020;324(5):460-470.
- 27. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. New England Journal of Medicine 2020;383(19):1827-1837.
- 28. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ 2020;369: m1849.
- 29. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-2052.

- 30. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Medecine et Maladies Infectieuse 2020;50(4):384.
- 31. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020;324(11):1048-1057.
- 32. Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine and Infectious Disease 2020;34:101663.
- 33. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang da xue xue bao. Yi xue ban 2020;49(2):215-219.
- 34. Simonovich VA, Pratx LDB, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. New England Journal of Medicine 2021;384(7):619-629.
- 35. Libster R, Marc GP, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. New England Journal of Medicine 2021;384(7):610-618.
- 36. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases 2020;97:396-403.
- 37. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P.
 Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371: m3939.

- 38. Million M, Lagier J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease 2020;35:101738.
- 39. Mahévas M, Tran V-T, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data. BMJ 2020;369:m1844.
- 40. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early covid-19: A randomized trial. Annals of Internal Medicine 2020;173(8):623-631.
- 41. Zhang B, Liu S, Tan T, et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest 2020;158(1):e9-e13. Cited 231 times.
- 42. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology 2020;92(10):1890-1901.
- 43. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Med 2020;1(1):114-127.e3.
- 44. Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Frontiers in Immunology 2020;11:1061.
- 45. Liu STH, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Medicine 2020;26(11):1708-1713.
- 46. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science 2020;35(14):e149.

- 47. Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. Journal of Clinical Investigation 2020;130(9):4791-4797.
- Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic Proceedings 2020;95(9):1888-1897.
- 49. Zeng Q-L, Yu Z-J, Gou J-J, et all. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients with Coronavirus Disease 2019. Journal of Infectious Diseases 2020;222(1):38-43.
- 50. Deftereos SG, Giannopoulos G, Vrachatis DA, et al. JAMA Network Open 2020;3(6):13136.
- 51. Saleh M, Gabriels J, Chang D, et al. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circulation: Arrhythmia and Electrophysiology, 2020;496-504.
- 52. Letrud K, Hernes S. Affirmative citation bias in scientific myth debunking: A three-inone case study. PLoS One. 2019 Sep 9;14(9):e0222213.
- 53. Frank RA, Sharifabadi AD, Salameh JP, McGrath TA, Kraaijpoel N, Dang W, Li N, Gauthier ID, Wu MZ, Bossuyt PM, Levine D, McInnes MDF. Citation bias in imaging research: are studies with higher diagnostic accuracy estimates cited more often? Eur Radiol. 2019 Apr;29(4):1657-1664.
- 54. Urlings MJE, Duyx B, Swaen GMH, Bouter LM, Zeegers MPA. Citation bias in the literature on dietary trans fatty acids and serum cholesterol. J Clin Epidemiol. 2019 Feb;106:88-97.

- 55. Misemer BS, Platts-Mills TF, Jones CW. Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis. Trials. 2016 Sep 28;17(1):473.
- 56. Urlings MJE, Duyx B, Swaen GMH, Bouter LM, Zeegers MP. Citation bias and other determinants of citation in biomedical research: findings from six citation networks. J Clin Epidemiol. 2021 Apr;132:71-78.
- 57. Kivimäki M, Batty GD, Kawachi I, Virtanen M, Singh-Manoux A, Brunner EJ. Don't let the truth get in the way of a good story: an illustration of citation bias in epidemiologic research. Am J Epidemiol. 2014 Aug 15;180(4):446-8.
- Else H. How a torrent of COVID science changed research publishing in seven charts. Nature 2020;588:553.
- 59. Ioannidis JPA, Salholz-Hillel M, Boyack KW, Baas J. The rapid, massive growth of COVID-19 authors in the scientific literature. Royal Soc. Open Sci. 2021, https://doi.org/10.1098/rsos.210389
- 60. Serghiou S, Marton RM, Ioannidis JPA. Media and social media attention to retracted articles according to Altmetric. PLoS One. 2021 May 12;16(5):e0248625.
- Tatsioni A, Bonitsis NG, Ioannidis JP. Persistence of contradicted claims in the literature. JAMA. 2007 Dec 5;298(21):2517-26.
- 62. Crichton ML, Goeminne PC, Tuand K, Vandendriessche T, Tonia T, Roche N, Chalmers JD; European Respiratory Society COVID-19 Task Force. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. Eur Respir Rev. 2021 Dec 15;30(162):210171.

- 63. World Health Organization. Therapeutics and COVID-19: living guideline, <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.3</u>, last accessed January 3, 2022.
- 64. <u>https://www.covid19treatmentguidelines.nih.gov/management/clinical-</u> <u>management/hospitalized-adults--therapeutic-management/</u>, last revised December 16, 2021, last accessed January 3, 2022.
- 65. Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1365-1376.
- 66. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807.
- 67. Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021 Jun 24;11(6):e048416.
- 68. Santenna C, Vidyasagar K, Amarneni KC, Ghanta SN, Sadasivam B, Pathan S, Padmavathi R. The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. Ther Adv Drug Saf. 2021 Sep 24;12:20420986211042517.
- 69. Cheng Q, Zhai G, Chen J, Jia Q, Fang Z. Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials. J Med Virol. 2021 Dec 9. doi: 10.1002/jmv.27512.

- 70. Axfors C, Janiaud P, Schmitt AM, Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. 2021 Nov 20;21(1):1170.
- 71. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in COVID-19 patients: a systematic review and meta-analysis of randomized clinical trials. JAMA. 2021 Feb 26. doi: 10.1001/jama.2021.2747
- 72. Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. Nature Communications 2021;12(1):2349.
- 73. Hardwicke TE, Szűcs D, Thibault RT, et al. Citation patterns following a strongly contradictory replication result: Four case studies from psychology. Advances in Methods and Practices in Psychological Science 2021;4(3):25152459211040837.
- 74. Bastiaansen JA, de Vries YA, Munafò MR. Citation distortions in the literature on the serotonin-transporter-linked polymorphic region and amygdala activation. Biological Psychiatry 2015;78(8):E35–E36.
- Greenberg SA. How citation distortions create unfounded authority: Analysis of a citation network. BMJ 2009;339:b2680.

Conflicts of interest: none

Funding: The work of John Ioannidis has been funded by an unrestricted gift from Sue and Bob O'Donnell to Stanford Prevention Research Center, Stanford University. Data sharing: all data are in the paper and in the supplementary table 1. Patient involvement: none